APAC IPOs & Placements, Aequitas Research

Clarence Chu

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

Fangzhou Pre-IPO - The Negatives - Hard to Shake off Loss-Making Tendencies

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Jiangsu Fangzhou Chemical / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/fangzhou-group" target="_blank" data-smartkarma-citation="entities:36560:1" rel="noopener">Fangzhou Group (FANGZHOU HK)</a> is looking to raise about US$300m in its upcoming Hong Kong IPO.</li>
<li>Fangzhou (FZ) is an online chronic disease management (CDM) service provider in China.</li>
<li>In this note, we will talk about the positive aspects of the deal.</li>
</ul>



Fangzhou Group (FANGZHOU HK) is looking to raise about US$300m in its upcoming Hong Kong IPO.
Fangzhou (FZ) is an online chronic disease management (CDM) service provider in China.
In this note, we will talk about the positive aspects of the deal.


Contemporary Amperex Technology (CATL) (300750 CH)

Qingdao Ainnovation Technology Group (2121 HK)

Fangzhou Pre-IPO - The Positives - Regulatory Changes and COVID Spurred Growth